Plasma exchange for myeloma kidney: cast(s) away?

Kidney Int. 2008 Jun;73(11):1211-3. doi: 10.1038/ki.2008.117.


Leung et al. (this issue) present a retrospective study of 40 patients. Observations in 14/40 led to the suggestion of restitution of plasma exchange for light-chain responsive, biopsy-proven myeloma kidney until a better randomized control trial (RCT) is constructed. A careful analysis of their study and a recent RCT suggest little difference in outcome between plasma exchange and control groups. The analysis supports restitution of a better RCT of plasma exchange for myeloma kidney rather than off-label use.

Publication types

  • Comment
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Female
  • Humans
  • Kidney Neoplasms / therapy*
  • Male
  • Middle Aged
  • Multiple Myeloma / therapy*
  • Plasma Exchange*